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 Advances in sequencing technology have led to the introduc-
tion of panel testing in hereditary breast and ovarian cancer. 
While direct-to-consumer testing services have become widely 
available, the clinical validity of many of the genes on panel 
tests remains contentious and risk management guidelines 
are often lacking. This article gives an overview of advantages 
with panel testing as well as important challenges, including 
clinical translation of test results. 
 Introduction 
 High-throughput sequencing of a number of genes (via targeted 
next-generation sequencing) at a declining cost is rapidly 
replacing sequential testing of single genes in both public and 
commercial service laboratories. The use of large multi-gene 
disease-targeted panels (see Table  1 ) is a cost-effective approach, 
also allowing incorporation of our improved understanding of 
the genetic architecture of disease. In this review, we focus on 
hereditary breast and ovarian cancer as a paradigm to illustrate 
the benefits and pitfalls of multi-gene panel testing in the clinic. 
 Susceptibility genes and panel testing 
 Germline mutations in the  BRCA1 and  BRCA2 genes remain 
the most important cause of familial forms of breast and 
ovarian cancer. 1 Identification of a deleterious  BRCA1/2 variant 
within a family has profound implications in risk management, 
including enhanced surveillance, prophylactic surgery and 
chemoprevention options. 2 However, in many families with a 
strong history of breast and/or ovarian cancer,  BRCA1/2 testing 
does not identify a causative mutation. 
 Since the discovery of the  BRCA1 and  BRCA2 genes in the 
mid-1990s, numerous other susceptibility genes for breast or 
ovarian cancer have been identified (Table  2 ). Rare mutations 
in  CDH1, PTEN, STK11 and  TP53 genes, associated with 
hereditary diffuse gastric cancer, Cowden syndrome, Peutz-
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Jeghers syndrome and Li Fraumeni syndrome, respectively, can 
confer a high risk of breast cancer. 1,3 Besides these, intermediate 
breast cancer risk genes, such as  ATM, CHEK2, and  PALB2, 
have been identified. 1,3 Large-scale genotyping studies have 
also led to the identification of numerous low risk variants, 
predominantly consisting of single nucleotide polymorphisms 
in non-coding sequences. 4,5 Inherited mutations in other genes, 
such as  RAD51C, RAD51D and  BRIP1, and mismatch-repair 
(MMR) genes ( MLH1, MSH2, MSH6, PMS2, EPCAM ) that 
cause Lynch syndrome when mutated, also influence the risk of 
ovarian cancer. 6 
 These genetic discoveries have occurred alongside major 
advances in sequencing technology that has led to the 
introduction in the clinic of simultaneous testing of panels 
of selected multiple genes for hereditary breast and ovarian 
cancer predisposition. 1 In theory, panel testing for hereditary 
breast and ovarian cancer allows for a more comprehensive 
Key points
 Additional susceptibility genes for familial breast and ovarian 
cancer have been identiﬁed since the discovery of the  BRCA1/2 
genes in the mid-1990s. 
 Deleterious mutations confer different levels of cancer risks, with 
lack of sufﬁcient evidence for clinical actionability in many of 
these new genes. 
 Advances in sequencing technology led to the introduction 
of simultaneous multi-gene (panel) testing which is rapidly 
replacing sequential single-gene testing in public and 
commercial service laboratories. 
 Panel testing for familial breast/ovarian cancer has a slightly 
increased diagnostic yield compared to conventional  BRCA1/2 
testing. 
 There is a lack of consensus guidelines on panel testing, 
including eligibility criteria and clinical translation of results. 
 KEYWORDS: gene panel, breast cancer, ovarian cancer, genetic 
testing and hereditary cancer. 
CMJv17n6-Prapa.indd   568 11/18/17   12:16 PM
CME Genetic medicine
© Royal College of Physicians 2017. All rights reserved. 569
risk assessment, incorporating up-to-date knowledge on 
risk variants. Moreover, it may allow risk stratification 
in individuals who would not otherwise meet traditional 
testing criteria based on prior syndrome-focused approaches. 
However, panel testing is not without its limitations, including 
interpretation of results and subsequent risk management, 
especially in the absence of consensus guidelines. 
 Availability and testing criteria 
 Since the US Supreme Court decision in 2013 against Myriad 
Genetics’ patent claims for  BRCA1/2 testing, a number of 
gene panel testing services for hereditary breast and ovarian 
cancer, including  BRCA1/2 genes have become available. 1 These 
cover different combinations of genes with varying degrees 
of evidence of an association with breast and/or ovarian 
cancer which can be counterproductive where the evidence is 
limited. A case in point is  BRIP1 , which was first reported to 
be associated with breast cancer in 2006, 7 an observation that 
was not substantiated by a much larger study published ten 
years later. 8 Yet this gene is still found on many commercially 
available hereditary breast cancer panels. 1 In contrast, screening 
for single nucleotide polymorphisms is not typically included 
in panel tests, although it has been estimated that they can 
cumulatively confer a risk of 29% (by age 80 years for women 
in the top 1% for polygenic risk score 4 ) which is comparable to 
moderate risk susceptibility genes (30% and 28% for  CHEK2 
and  ATM , respectively 9 ). 
 While testing criteria for germline  BRCA1/2 gene mutations 
are well defined, there are no equivalent guidelines for multi-
gene panel testing in familial breast–ovarian cancer. In a 
UK-based survey conducted in 2016, 8 out of 19 participating 
centres offered panel testing in selected individuals following 
discussion at the weekly departmental meeting (personal 
communication by MT and JS). In some centres,  BRCA1/2 
testing was routinely run on a panel, with data on other genes 
reported upon the clinician’s request. Eligibility criteria varied 
widely from centre to centre. 
 In the commercial setting, panel tests for breast cancer, such 
as the 17-gene BreastNext test by Ambry Genetics, are generally 
marketed to women who had uninformative  BRCA1/2 testing 
and either have a personal history of early onset breast cancer 
(diagnosed ≤ 45 years) or multiple close family members 
with breast and other cancers. Similarly, a 13-gene familial 
breast–ovarian cancer panel is available on the UKGTN with 
minimum requirements including the equivalent criteria for 
 BRCA1/2 testing. 10 These observations highlight the current 
inconsistencies in panel testing for breast and/or ovarian 
cancer susceptibility, in both clinical and commercial settings, 
and that access is largely dependent on availability and local 
guidelines. 
 Diagnostic yield and variant interpretation 
 Numerous studies have assessed the performance of targeted 
next-generation sequencing for the diagnosis of familial 
breast and ovarian cancer (Table  3 ). The analytical validity 
of panel testing was comparable to traditional sequencing 
methods (separate Sanger sequencing and deletion/duplication 
analyses of each gene). 11,12 Overall, ‘high-risk’ breast cancer 
susceptibility genes are thought to account for 20–25% of 
familial breast cancer, with ‘intermediate’ risk genes explaining 
a further 5% and ‘low risk’ gene variants cumulatively covering 
an additional 14% of the familial risk. 12 
 In a recent study by Desmond  et al , 13 panel testing in 1046 
 BRCA1/2 -negative cases referred for hereditary breast–ovarian 
cancer predisposition led to identification of deleterious 
mutations in other hereditary cancer predisposition genes 
 Table 1.  Examples of disease-targeted gene panels available via UKGTN where testing criteria and a gene 
dossier on prevalence and sensitivity of mutation detection is also included. 10 Websites such as GeneReviews 
and OMIM (Online Mendelian Disorder in Man) provide clinicians with up-to-date information on genes associated 
with a Mendelian disorder in question. A comprehensive directory of available genetic testing services can then be 
accessed via webpages, such as UK Genetic Testing Network (UKGTN) and European Directory of DNA Diagnostic 
Laboratories (EDDNAL). 
Disease category Disease Genes 
Hereditary cancer Familial breast/ovarian cancer  ATM, BARD1, BRIP1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, 
PTEN, PIK3CA, STK11, TP53 
Familial bowel cancer including hereditary 
nonpolyposis colorectal cancer (HNPCC) 
phenotype or polyposis
 APC, BMPR1A, POLD1, POLE, KIT, MLH1, MSH2, MSH6, 
MUTYH, PDGFRA, PMS2, GALNT12, STK11, SMAD4 
Cardiac disorders Familial hypertrophic cardiomyopathies  ACTC1, CSRP3, FHL1, GLA, LAMP2, MYBPC3, MYL2, MYL3, 
MYLK2, MYH6, MYH7, NEXN, PLN, PRKAG2, SLC25A4, TTN 
Aortopathy disorders  ACTA2, COL3A1, FBN1, FBN2, MYH11, SMAD3, SLC2A10, 
TGFB2, TGFB3, TGFBR1, TGFBR2 
Neurological and 
neuromuscular disorders
Early infantile epileptic encephalopathy  ALDH7A1, ARHGEF9, ARX, BTD, CHD2, CNTNAP2, CDKL5, 
FOXG1, GABRB3, GABRG2, GLUD1, GRIN2B, HCN1, POLG 
Congenital muscular dystrophies  B3GALNT2, CHKB, COL4A1, COL4A2, COL6A1, COL6A2, 
COL6A3, COL12A1, DOLK, DPM1, DPM2, DPM3, DAG1, 
FKTN, FKRP, GMPPB, ITGA7, ITGA9, ISPD, LAMA2 
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in 3.8% of individuals, which was consistent with previous 
similar studies. 12 , 14–16 In the majority of these (26/40), the 
identified variant was in ‘low-moderate risk’ breast–ovarian 
cancer susceptibility genes, such as  CHEK2 , with another 
eight cases harbouring mutations in genes associated with 
Lynch syndrome (which are not proven to cause breast cancer), 
and only three variants detected in high-risk breast cancer 
genes (all in  CDH1 ). Apart from the increased likelihood of 
identifying a disease-causing mutation, panel testing can also 
lead to unexpected (incidental) findings in ‘atypical’ cases. For 
example, panel testing in 360 women with primary ovarian, 
peritoneal, or fallopian tube carcinoma led to identification of 
two  MSH6 deleterious germline mutations in individuals with 
no family history of Lynch syndrome and three  TP53 mutation 
carriers without a family history of Li-Fraumeni syndrome. 16 
Identifying such unexpected deleterious germline mutations 
could have implications for unaffected family members by way 
of cascading genetic tests, risk-assessment and future screening 
advice. 
 An important challenge for laboratories performing next-
generation sequencing is the interpretation of identified 
variants, especially in genes other than  BRCA1/2 where 
available evidence is less well established. Although there is 
evidence of pathogenicity for protein-truncating variants 
(assumed to result in loss of function) for most genes included 
in hereditary breast–ovarian gene panels, the interpretation 
of missense variants is much more challenging. Missense 
variants in the coding region of genes that do not interfere 
with the reading frame are common and sometimes 
misinterpreted as pathogenic. Interpretation of these generally 
relies on use of  in silico prediction tools, conservation data 
to assess if the variant is present in other species, familial 
segregation studies, and possibly tumour studies. 1 Another 
useful tool can be the assessment of a variant frequency in 
affected and non-affected cohorts from multi-ethnic groups 
but this is dependent on the establishment and maintenance 
of international databases. 
 As a result of the above, the likelihood of identifying so-
called variants of uncertain significance (VUS) is high. In 
a study by Kurian  et al assessing the performance of panel 
testing in 175 women meeting  BRCA1/2 gene testing criteria, 
sequencing of 39 genes led to identification of 2.1 VUS on 
average per participant, out of which the vast majority (88.8%) 
were novel. 17 Similarly, one third (168/488) of women with 
breast cancer undergoing sequencing of 25 breast/ovarian 
cancer susceptibility genes harboured VUS, with as many as 
three variants found per patient. 18 Most VUS will likely turn 
out to be non-pathogenic, but until this is known they will 
remain a source of considerable anxiety for the patient and 
their family. 
 Clinical translation of results 
 Most familial breast–ovarian cancer panels include moderate 
risk susceptibility genes for which consensus guidelines for risk 
management are not widely established and only beginning 
to be addressed in part. 19,20 For many of these genes, there 
is limited evidence on the degree of associated cancer risk. 
For example, most existing data on  CHEK2 gene derive from 
the 1100delC variant, which is the commonest truncating 
variant in northern European populations. 1 Mutations in 
three other genes,  BRIP1, RAD51C, and  RAD51D, have been 
clearly associated with ovarian cancer but there is conflicting 
and limited evidence regarding their association with breast 
cancer. 1 
 Thus a mutation-positive result arising from panel testing may 
not necessarily be clinically actionable. In the aforementioned 
study by Desmond  et al , the most common deleterious 
mutations in  BRCA 1/2-negative cases were identified in low 
to moderate breast cancer risk genes with a recommended 
management change in the minority of these by either increased 
screening or prophylactic breast surgery (in the context of 
significant family history) based on National Comprehensive 
Cancer Network (NCCN) guidelines. 13 Notably, there are no 
equivalent gene-specific NICE guidelines on the management 
 Table 2.  Breast and ovarian cancer susceptibility 
genes (excluding  BRCA1/2 genes). 
Gene OMIM 
gene ID 
Associated syndrome and/or other 
cancers 
Breast cancer susceptibility genes
High risk
 CDH1 602118 Diffuse gastric cancer
 PTEN 601728 Cowden syndrome (thyroid, endometrial 
cancer)
 STK11 602216 Peutz-Jeghers syndrome (colon, pancreas, 
ovarian sex cord-stromal tumours)
 TP53 191170 Li Fraumeni syndrome (sarcoma, 
adrenocortical carcinoma, brain 
tumours)
Intermediate risk
 ATM 607585 Ataxia telangiectasia (pancreas)
 CHEK2 604373
 NF1 613113 Neurofibromatosis Type I (malignant 
tumours of peripheral nerve sheath, brain, 
central nervous system)
 PALB2 610355 Pancreas
Unknown/disputed risk
 BRIP1 605882 Ovary ( moderate risk )
 NBN 602667 Unknown
 RAD51C 602774 Ovary ( moderate risk )
 RAD51D 602954 Ovary ( moderate risk )
Ovarian cancer susceptibility genes
 BRIP1 605882
 EPCAM 185535 Lynch syndrome (colon, endometrium, 
stomach, small intestine, hepatobiliary 
tract, urinary tract, brain, skin)
 MLH1 120436 Lynch syndrome
 MSH2 609309 Lynch syndrome
 MSH6 600678 Lynch syndrome
 RAD51C 602774
 RAD51D 602954
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However, one could argue that if a woman’s mutation status for 
these genes does not change her clinical management, there is 
little to be gained for testing them in the first place. 
 Conclusion 
 In the era of next-generation sequencing with continuously 
falling prices, the need for complex eligibility criteria for panel 
testing may be eliminated. Revision of the NICE guidelines in 
2013 lowered the threshold for  BRCA1/2 germline mutation 
testing, which is now offered to all individuals and their relatives 
who have a  > 10% (instead of 20%) likelihood of having a 
mutation based on risk algorithms, such as BOADICEA and 
the Manchester scoring system. 21 Panel tests for familial breast/
ovarian cancer in the US typically cost around $1500–3000 and 
include 10–30 genes, although the price is coming down rapidly 
with some companies offering panel tests for as little as $300; 
in the UK, 13-gene panel testing costs around £600–800 versus 
 BRCA1/2 testing in the region of £400. 10 
of women who carry deleterious mutations in genes other than 
 BRCA1/2 and genes associated with rare conditions that carry a 
high risk of breast cancer (see Table  2 ). 21 
 Another important aspect of panel testing is the value 
of a negative result in an unaffected relative for a familial 
deleterious variant in an intermediate cancer risk gene. 
Incorporation of truncating mutations in three intermediate 
breast cancer risk genes ( ATM, CHEK2, and  PALB2 ) to the 
BOADICEA risk-prediction algorithm, illustrated that the 
reduction in risk for women whose mother carried a  PALB2 
mutation was comparable to a  BRCA2 mutation, whereas 
negative testing for an  ATM or  CHEK2 familial mutation 
in the same scenario only led to a slight decrease in risk, 
even with a strong family history (Fig  1 ). 9 In line with the 
above, a counselling framework has been recently proposed 
for moderate penetrance cancer-susceptibility mutations, 
suggesting that relatives who test negative for the familial 
mutation should be managed on the basis of their family 
history and may still warrant some enhanced surveillance. 20 
 Table 3.  Summary of panel testing studies in familial breast and/or ovarian cancer. 
Study Diseases N subjects N 
genes 
N deleterious 
 BRCA1/2 
mutations (%) 
N deleterious 
mutations in all 
other genes (%) 
Walsh  et al , 2011 16 Ovarian, fallopian tube, peritoneum 360 21 63 (17.5) 22 (6.1)
Castera  et al , 2014 12 Hereditary breast/ovarian cancer 708 27 66 (9.3) 44 (6.2)
Kurian  et al , 2014 17 Hereditary breast/ovarian cancer 198 42 57 (28.8) 16 (8.0)
LaDuca  et al , 2014 14 Ambry-tested, non  BRCA1/2 874 (breast panel) 
223 (ovarian panel)
14–22 0 (by definition) 65 (7.4) for breast 
panel 16 (7.2) for 
ovarian panel
Couch  et al , 2014 22 Triple-negative breast cancer 1824 17/122 204 (11.1) 67 (3.7)
Maxwell  et al , 2014 15 Breast cancer <40 years, non  BRCA1/2 258 22 0 (by definition) 31 (11)
Tung  et al , 2015 23 Myriad tested 1781 25 165 (9.3) 79 (4.4)
Desmond  et al , 
2015 13 
Hereditary breast/ovarian cancer 
(Invitae or Myriad tested), non  BRCA1/2 
1046 25–29 0 (by definition) 40 (3.8)
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 Fig 1.  Value of negative testing for familial deleterious variants in moderate/high risk breast cancer genes. (a) shows the BOADICEA predicted breast 
cancer risk for negative testing (coloured curves) and based on family history alone (black curve). The proband, highlighted with an arrow in pedigree  (b) , is 
assumed to be a 20 year old woman in the United Kingdom. As illustrated, the reduction in risk following negative testing for a  PALB2 familial mutation is com-
parable to a  BRCA2 mutation whereas negative testing for an  ATM or  CHEK2 familial mutation is associated with a smaller decrease in risk. Image adjusted 
from Lee  et al ., with permission. 9 
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 Despite the above, panel testing is unlikely to overtake clinical 
acumen in the medium term, considering its limitations and 
our current gap in knowledge. The complexity of human 
variation, such as missense variants and incomplete penetrance 
due to environmental and other gene modifier factors, 
means that genetic data can at most add predictive value and 
always need to be interpreted within a clinical context. In 
the future, clinical geneticists may devolve diagnostic panel 
testing to mainstream specialties but would support them 
through interpretation of results and cascading genetic tests 
to relatives. Importantly, the absence of a pathogenic variant 
does not necessarily exclude the presence of familial and/or 
other inherited susceptibility factors and therefore, genetic 
counselling should still be considered an integral part of the 
process. ■ 
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